1
|
Nasonov EL, Reshetnyak TM, Solovyev SK, Popkova TV. [Systemic lupus erythematosus and antiphospholipid syndrome: past, present, future]. TERAPEVT ARKH 2023; 95:365-374. [PMID: 38158987 DOI: 10.26442/00403660.2023.05.202246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Accepted: 07/16/2023] [Indexed: 01/03/2024]
Abstract
Immune-inflammatory (autoimmune and autoinflammatory) rheumatic diseases are widespread severe chronic inflammatory diseases and also "models" for studying the fundamental mechanisms of pathogenesis and approach to pharmacotherapy of other diseases associated with autoimmunity and/or autoinflammation. Uncontrolled inflammation leading to hypercoagulation forms the basis of "thromboinflammation", which is considered a universal pathogenetic mechanism of organ involvement in immune-inflammatory rheumatic diseases, as well as in COVID-19 and atherosclerotic vascular lesions (atherothrombosis). Thrombo-inflammatory mechanisms play a crucial role in systemic lupus erythematosus and antiphospholipid syndrome. Russian rheumatology, under the leadership of academician Valentina Alexandrovna Nasonova, greatly contributed to the research of these disorders. This article addresses the current view about the overlapping pathogenetic mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome, the relevance of these studies during the COVID-19 pandemic, and the prospects for antithrombotic and anti-inflammatory therapy.
Collapse
Affiliation(s)
- E L Nasonov
- Nasonova Research Institute of Rheumatology
- Sechenov First Moscow State Medical University (Sechenov University)
| | | | | | | |
Collapse
|
2
|
Gerasimova EV, Popkova TV, Shalygina MV, Kirillova IG, Gerasimova DA, Glukhova SI, Nasonov EL. [Subclinical atherosclerosis of the carotid arteries in patients with rheumatoid arthritis with low cardiovascular risk]. TERAPEVT ARKH 2023; 95:375-379. [PMID: 38158988 DOI: 10.26442/00403660.2023.05.202203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Accepted: 07/16/2023] [Indexed: 01/03/2024]
Abstract
AIM To evaluate the detection rate of subclinical carotid atherosclerosis in rheumatoid arthritis (RA) patients with low cardiovascular risk (CVR). MATERIALS AND METHODS The study included 182 RA patients with low CVR (mSCORE<1%) and no established cardiovascular diseases and a control group comprising 100 people. Atherosclerotic lesion of the carotid arteries was assessed using Doppler ultrasound of the carotid arteries and was determined by the detection of atherosclerotic plaque (ASP) - the local increase in the thickness of the intima-media complex (IMT) >1.5 mm. RESULTS Carotid ASP were observed more frequently in RA patients with low CVR than in the control group (17% versus 8%; p=0.02). The frequency of ASP in RA patients with low CVR did not depend on the disease's stage or activity and ongoing therapy. In RA, the detection of subclinical atherosclerosis was associated with traditional risk factors: carotid ASP were detected 4 times more often in men than in women (48% versus 12%, p<0.01); carotid IMT correlated with age (R=0.46), body mass index (R=0.17), LDL-C level (R=0.20), systolic blood pressure (R=0.17); p<0.05 in all cases. According to a multivariate model, in RA, the risk of developing ASP increased in the presence of dyslipidemia (odds ratio - OR 2.97; 95% confidence interval - CI 1.36-6.49; p=0.006) and arterial hypertension (OR 2.16; 95% CI 1.03-4.54; p=0.04). In RA patients with carotid ASP, sCD40L level was associated with carotid IMT (R=0.32; p=0.04) and cholesterol concentration (R=0.39; p=0.01). CONCLUSION Subclinical atherosclerotic lesions of the carotid arteries were observed in 24% of RA patients with low cardiovascular risk and were detected almost 2 times more often than in the control group. In RA patients with low CVR, the risk of developing carotid ASP increased by 2-3 times with concomitant hypertension and dyslipidemia. The carotid IMT was associated with traditional risk factors - age, gender, lipid levels and blood pressure indicators, in cases of detection of ASP - with an immunoinflammatory marker - sCD40L.
Collapse
Affiliation(s)
| | | | | | | | - D A Gerasimova
- Sechenov First Moscow State Medical University (Sechenov University)
| | | | - E L Nasonov
- Nasonova Research Institute of Rheumatology
- Sechenov First Moscow State Medical University (Sechenov University)
| |
Collapse
|
3
|
Moroz EV, Popkova TV, Moroz AE. Manifestations of the gastrointestinal tract in systemic rheumatic diseases: A narrative review. Naučno-praktičeskaâ revmatologiâ 2022. [DOI: 10.47360/1995-4484-2022-578-586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Gastrointestinal disorders are important place among the visceral manifestations of systemic autoimmune and immunoinflammatory rheumatic diseases (RD). Pathology of the esophagus, stomach, small and large intestine can vary from moderate functional disorders to the development of severe chronic inflammation with metaplasia and dysplasia of the mucous membrane, the formation of multiple erosions, hemorrhages and deep ulcers. Complications of gastrointestinal pathology in RD, such as bleeding, perforations and strictures, can cause death. This review examines the main clinical manifestations, possibilities of diagnosis and treatment of gastrointestinal lesions in systemic scleroderma, idiopathic inflammatory myopathies, systemic vasculitis, Sjogren’s syndrome and disease, as well as systemic lupus erythematosus.
Collapse
Affiliation(s)
- E. V. Moroz
- Main Military Clinical Hospital named after N.N. Burdenko
| | | | - A. E. Moroz
- V.A. Nasonova Research Institute of Rheumatology
| |
Collapse
|
4
|
Kirillova IG, Gorbunova YN, Popkova TV, Diatroptov ME, Nasonov EL. Subclinical left ventricular dysfunction and N-terminal pro-brain natriuretic peptide in patients with rheumatoid arthritis. Naučno-praktičeskaâ revmatologiâ 2022. [DOI: 10.47360/1995-4484-2022-560-565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aim – to determine the frequency of myocardial dysfunction using echocardiography with speckle tracking (STE) method, the relationship between a low global longitudinal strain (GLS) with the level of NT-proBNP, clinical and laboratory manifestations of rheumatoid arthritis. Material and methods. The study included 43 patients with RA (ACR/EULAR criteria, 2010): 79% women, age – 53.0 [38.0; 63.0] years, disease duration – 60.0 [36; 180] months; DAS28 – 5.9 [5.2; 6.4], positive for ACCP (74%), RF IgM (81%), without prior biological therapy and CVD. Methotrexate was received by 44%, leflunomide – 35%, sulfasalazine – 9.3%, hydroxychloroquine – 7%, glucocorticoids – 67.4%, non-steroidal anti-inflammatory drugs – 74% of patients with RA. All RA patients underwent echocardiography – tissue Doppler and STE. The level of NT-proBNP was determined in the blood serum The normal range for NT-proBNP was less than 125 pg/ml.Results. Low GLS was observed in 26 (61%) patients with RA. RA patients had a decrease GLS, E LV, E’ LV, E/A LV compared with the control group. Left ventricular diastolic dysfunction (LVDD) was higher in RA patients (13 (31%) vs 0%). Patients with RA had significantly higher levels of NT-proBNP (114.8 [45.1; 277.5] and 52 [40.5; 69.1] pg/ml) compared with the control group. There were correlations between a low GLS and DAS28 (r=0.9), the number of painful joints (r=0.6), radiological stage (r=0.6) and the presence of systemic manifestations (r=0.5), age (r=–0.9), E LV velocity (r=–0.5) (p<0.05 in all cases). There were correlations between the level of NT-proBNP and the E/A LV ratio (r=–0.4), A LV velocity (r=0.5) (p><0.05 in all cases).>< 0.05 in all cases). There were correlations between the level of NT-proBNP and the E/A LV ratio (r=–0.4), A LV velocity (r=0.5) (p< 0.05 in all cases).Conclusions. In RA patients with a high frequency the low GLS LV was detected, which is associated with a high activity of the inflammatory process. STE helps to detect myocardial dysfunction in patients with RA at earlier stages than tissue Doppler. The use of STE, the determination of the level of NT-proBNP make it possible to diagnosing preclinical disorders of systolic and diastolic functions of the LV, which can contribute to the early initiation of therapy and improve the prognosis in this category of patients.
Collapse
Affiliation(s)
| | | | | | | | - E. L. Nasonov
- V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
| |
Collapse
|
5
|
Fomicheva OA, Popkova TV, Gerasimova EV, Krougly LB, Pogorelova OA, Balakhonova TV, Karpov YUA, Tripoten MI. Factors of atherosclerosis progression in rheumatoid arthritis, prospective study data. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Aim of the study
Determine in prospective observation study the factors of progression of atherosclerosis in pts with rheumatoid arthritis (RA) during 3 yrs.
Matherial and methods
This prospective study included 124 patients with RA and suspected ischemic heart disease (IHD), the average age was 58 [52; 63] years. Follow-up period was 3 years (37.5 moths). All RA pts were examined and had treatment, according to European and National guidelines for the diagnosis and treatment of stable CAD (2013) and EULAR for RA (2016). Carotid ultrasound and coronary angiography were also completed. In course of all RA pts the following risk factors were assessed: arterial hypertension (AH), smoking, overweightbody (BMI), heredity for cardiovascular diseases (CVD), diabetes mellitus (DM), dyslipidemia (DLP). The laboratory studies were: CBC and total cholesterol (TC), HDL-C, LDL-C, TG, highly sensitive C-reactive protein (hs-CRP), RA detected activity markers: rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (ACCP), index DAS28. Pro-inflammatory cytokines -interleukin (IL) -1-beta, IL-6, tumor necrosis factor alpha (TNF alpha) were assessed in single RA pts once after 3 years of observation.
Results
The median duration of RA in inclusion in the study was 11 years, the DAS28 index was 3.8 points (middle degree of activity). DLP was detected in 41% RA pts. DM was in 13% pts. In RA pts, initially atherosclerotic plaques with stenosis of the carotid arteries (CA) 20% or more in 94 pts (77%) were revealed, in 3 of them CA stenosis exceeded 50%. 90 RA pts (72%) were examined again. 21 pts had signs of progressing atherosclerosis marked in CA and/or coronary arteries: 12 (13%) RA patients had only progression of atherosclerosis of CA, 7 (8%) - only progression of atherosclerosis of coronary arteries, 2 (2%) had both progression CA and coronary arteries. There are 2 formed subgroups of RA pts: Gr1 with the progression of atherosclerosis (n=21) and Gr 2 without progression of atherosclerosis (n=69). There are no differences between groups of risk factors of atherosclerosis development age, AH, BMI, lipids,TG, hs CRP, index DAS28.
Following rick factors: smoking (n=12 (57%) vs n=21 (30%)), heredity for CVD (n=11 (52%) vs n=17 (25%)), RA duration (13 yrs [10; 18] vs 12 years [6; 18]) were often revealed among pts of Gr 1. All differences p>0.05
Immunological data TNF alfa level, (8,08 [2,3; 8,44] pg/ml vs 1,22 [0,13; 8,00] pg/ml), IL-1β level, 3,97 [3,56; 4,10] pg/ml vs 3,52 [0,30; 4,53] pg/ml, and IL-6 level 3,50 [2,92; 5,76] pg/ml vs 2,52 [0,92; 4,36] pg/ml were significant higher in Gr1 than in Gr2. All differences was p>0.05.
Conclusion
The progression of atherosclerosis in RA with a low and moderate degree of activity of the disease occurs despite antirheumatic and lipid-lowering therapy. The development of atherosclerosis in this disease is defined by lipid, inflammatory and immunological disorders.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Russion National Cardiology Research Center Ministry of Health of Russion Federation
Collapse
Affiliation(s)
- O A Fomicheva
- Russian Cardiology Research and Production Complex, Angiology Department, Moscow, Russian Federation
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russian Federation
| | - E V Gerasimova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russian Federation
| | - L B Krougly
- Russian Cardiology Research and Production Complex, Angiology Department, Moscow, Russian Federation
| | - O A Pogorelova
- Russian Cardiology Research and Production Complex, Angiology Department, Moscow, Russian Federation
| | - T V Balakhonova
- Russian Cardiology Research and Production Complex, Angiology Department, Moscow, Russian Federation
| | - Y U A Karpov
- Russian Cardiology Research and Production Complex, Angiology Department, Moscow, Russian Federation
| | - M I Tripoten
- Russian Cardiology Research and Production Complex, Angiology Department, Moscow, Russian Federation
| |
Collapse
|
6
|
Simanenkov VI, Maev IV, Tkacheva ON, Alekseenko SA, Andreev DN, Bordin DS, Vlasov TD, Vorobyeva NM, Grinevich V, Gubonina IV, Drobizhev MY, Efremov NS, Karateev АE, Kotovskaya YV, Kravchuk IA, Krivoborodov GG, Kulchavenya EV, Lila AM, Mayevskaya MV, Poluektova EA, Popkova TV, Sablin OA, Solovyeva OI, Suvorov AN, Tarasova GN, Trukhan DI, Fedotova AV. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovasc Ther Prev 2021. [DOI: 10.15829/1728-8800-2021-2758] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- V. I. Simanenkov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - I. V. Maev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - O. N. Tkacheva
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - S. A. Alekseenko
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - D. N. Andreev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - D. S. Bordin
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - T. D. Vlasov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - N. M. Vorobyeva
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - V. Grinevich
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - I. V. Gubonina
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - M. Yu. Drobizhev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - N. S. Efremov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - А. E. Karateev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - Yu. V. Kotovskaya
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - Iu. A. Kravchuk
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - G. G. Krivoborodov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - E. V. Kulchavenya
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - A. M. Lila
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - M. V. Mayevskaya
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - E. A. Poluektova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - T. V. Popkova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - O. A. Sablin
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - O. I. Solovyeva
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - A. N. Suvorov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - G. N. Tarasova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - D. I. Trukhan
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - A. V. Fedotova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| |
Collapse
|
7
|
Fomicheva OA, Popkova TV, Krougly LB, Gerasimova EV, Novikova DS, Pogorelova OA, Tripoten MI, Balakhonova TV, Karpov YA, Nasonov EL. Factors of Progression and Occurrence of Atherosclerosis in Rheumatoid Arthritis. ACTA ACUST UNITED AC 2021; 61:12-21. [PMID: 33734051 DOI: 10.18087/cardio.2021.1.n1331] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Revised: 10/09/2020] [Accepted: 10/26/2020] [Indexed: 11/18/2022]
Abstract
Aim To determine in a prospective study factors of progressive atherosclerotic lesion of blood vessels in patients with rheumatoid arthritis (RA).Material and methods This prospective study included 124 patients with RA and suspected ischemic heart disease (IHD) and 30 patients with IHD (comparison group) aged 58 [52; 63] years. On enrollment to the study and at 3 years of follow-up, all patients underwent clinical and instrumental examination according to European and Russian guidelines for diagnosis and treatment of stable IHD (2013), including coronography as indicated. For all RA patients of the comparison group, risk factors (RF) were evaluated, including arterial hypertension, smoking, excessive body weight, family history of cardiovascular diseases (CVD), diabetes mellitus, and dyslipidemia. The following laboratory data were evaluated: blood count; biochemistry, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), rheumatoid factor (RhF), cyclic citrullinated peptide antibodies, and high-sensitivity C-reactive protein (hsCRP). Proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF- α), were measured in RA patients once, at 3 years of follow-up.Results Incidence of FRs for CVD was similar in RA patients and in the comparison group. Median RA duration before inclusion into the study was 11 years, and median DAS28 index score was 3.8. Incidence of dyslipidemia due to increased TC, LDL-C, and HDL-C was higher for RA patients at baseline. The LDL-C goal (<1.8 mmol/l) was achieved only in 3 (10 %) patients of the comparison group and 10 (8 %) RA patients. RA patients had higher levels of the inflammation indexes, hsCRP (0.75 mg/dl vs. 0.16 mg/dl; p<0.05) and erythrocyte sedimentation rate (ESR) (15 mm/h vs. 11.5 mm/h; p<0.05). In the RA group at baseline, atherosclerotic plaques with carotid artery (CTA) stenosis of 20% or more were found in 94 (77 %) patients; in 3 of them, CA stenosis was >50%. Patients with RA frequently had unchanged or slightly changed coronary arteries (CA) (47% of patients), and less frequently they had hemodynamically significant multi-arterial coronary atherosclerotic lesions (7 % vs. 57 % of patients in comparison group). At 37.5 months, 21 (23 %) of 94 RA patients had progressive atherosclerosis in CA and/or CTA; 12 (13 %) RA patients had only progressive CA atherosclerosis; 7 (8 %) had only progressive CTA atherosclerosis; and 2 (2 %) had simultaneous progression of CA and CTA atherosclerosis. Two groups of RA patients were formed, with the progression of atherosclerosis (n=21) and without the progression of atherosclerosis (n=69). RFs for the development/progression of atherosclerosis in RA patients included smoking, family history of CVD, and duration of the disease. Levels of lipids did not differ. Levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α) were higher in RA patients with progressive atherosclerosis. No effects of the anti-rheumatic therapy on the progression of atherosclerosis were observed.Conclusion Progression of atherosclerosis in RA remains in disease with low and moderate activity during the anti-rheumatic and hypolipidemic treatment. The development of atherosclerosis in RA is determined by lipid, inflammatory, and immune disorders.
Collapse
Affiliation(s)
- O A Fomicheva
- National medical research center of cardiology of Russian Federation Ministry of Health, Moscow
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow
| | - L B Krougly
- National medical research center of cardiology of Russian Federation Ministry of Health, Moscow
| | - E V Gerasimova
- V.A. Nasonova Research Institute of Rheumatology, Moscow
| | - D S Novikova
- V.A. Nasonova Research Institute of Rheumatology, Moscow
| | - O A Pogorelova
- National medical research center of cardiology of Russian Federation Ministry of Health, Moscow
| | - M I Tripoten
- National medical research center of cardiology of Russian Federation Ministry of Health, Moscow
| | - T V Balakhonova
- National medical research center of cardiology of Russian Federation Ministry of Health, Moscow
| | - Yu A Karpov
- National medical research center of cardiology of Russian Federation Ministry of Health, Moscow
| | - E L Nasonov
- V.A. Nasonova Research Institute of Rheumatology, Moscow
| |
Collapse
|
8
|
Kirillova IG, Novikova DS, Popkova TV, Udachkina HV, Markelova EI, Gorbunova YN, Korsakova YO, Gluchova SN. Chronic Heart Failure in Early Rheumatoid Arthritis Patients Prior to Basic Antirheumatic Therapy. Racionalʹnaâ farmakoterapiâ v kardiologii 2020. [DOI: 10.20996/1819-6446-2020-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Aim. To study the clinical manifestations and factors associated with the presence of chronic heart failure (CHF) in patients with early rheumatoid arthritis (RA) prior to anti-inflammatory therapy. Material and methods. The study included 74 patients with valid diagnosis of RA (criteria ACR/EULAR, 2010), 56 women (74%), median age – 54 [46;61] years, disease duration – 7 [4;8] months; seropositive for IgM rheumatoid factor (87%) and/or antibodies to cyclic citrullinated peptide (100%) prior to taking disease modifying anti-rheumatic drugs and glucocorticoids. CHF was verified in accordance with actual guidelines. The assessment of traditional risk factors for cardiovascular diseases, echocardiography, tissue Doppler imaging, carotid artery ultrasound, were carried out before the start of therapy in all patients with early RA. The concentration of NT-proBNP was determined by electrochemiluminescence. The normal range for NT-proBNP was less than 125 pg/ml.Results. CHF was diagnosed in 24 (33%) patients: in 23 patients – CHF with preserved ejection fraction, in 1 patient – CHF with reduced ejection fraction. 50% of patients with RA under the age of 60 were diagnosed with CHF. NYHA class I was found in 5 (21%) patients, class II – in 15 (63%), class III – in 1 (4%). Positive predictive value of clinical symptoms did not exceed 38%. All patients with early RA were divided into two groups: 1 – with CHF, 2 – without CHF. Patients with RA+CHF compared with patients without CHF were older, had higher body mass index, frequency of carotid atherosclerosis, of ischemic heart disease (IHD), hypertension, C-reactive protein (CRP) levels and intima media thickness. Independent factors associated with the presence of CHF were identified by linear regression analysis: abdominal obesity, CRP level, systolic blood pressure, dyslipidemia, carotid intima thickness, IHD. The multiple coefficient of determination was R2=57.1 (R-0.76, p<0.001). Level of NT-proBNP in RA patients with CHF (192.0 [154.9; 255.7] pg/ml) was higher than in RA patients without CHF (77 [41.1; 191.2] pg/ml) and in control (49.0 [33.2; 65.8] pg/ml), p<0.0001 and p=0.01, respectively. To exclude CHF in patients with early RA, the optimal NT-proBNP level was 150.4 pg/ml (sensitivity – 80%, specificity – 79%), the area under the ROC curve = 0.957 (95% confidence interval 0.913-1.002, p<0.001).Conclusion. CHF was detected in a third of RA patients at the early stage of the disease. Factors associated with the presence of CHF were abdominal obesity, CRP level, systolic blood pressure, dyslipidemia, intima media thickness, IHD.
Collapse
Affiliation(s)
- I. G. Kirillova
- Research Institute of Rheumatology named after V.A. Nasonova
| | - D. S. Novikova
- Research Institute of Rheumatology named after V.A. Nasonova
| | - T. V. Popkova
- Research Institute of Rheumatology named after V.A. Nasonova
| | - H. V. Udachkina
- Research Institute of Rheumatology named after V.A. Nasonova
| | - E. I. Markelova
- Research Institute of Rheumatology named after V.A. Nasonova
| | | | | | - S. N. Gluchova
- Research Institute of Rheumatology named after V.A. Nasonova
| |
Collapse
|
9
|
Novikova DS, Udachkina HV, Kirillova IG, Popkova TV. Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs. Racionalʹnaâ farmakoterapiâ v kardiologii 2020. [DOI: 10.20996/1819-6446-2019-15-6-820-830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Chronic autoimmune inflammation is one of the leading risk factors for the development of chronic heart failure (CHF) in rheumatoid arthritis (RA). The purpose of the review is to analyze the results of investigations on the effects of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biological disease-modifying anti-rheumatic drugs (bDMARDs), and targeted csDMARDs on cardiac function and the risk of developing CHF in patients with RA. Methotrexate may reduce the CHF risk and have a positive effect on the course of this condition in patients with RA. Despite the data on the presence of leflunomide effects that impede myocardial remodeling, there is no evidence of the role of the drug in the prevention of CHF in RA patients. Hydroxychloroquine may contribute to the prevention of CHF, but the risk of developing severe cardiotoxicity should be considered when taking the drug for a long time. Most studies have not revealed the negative effect of tumor necrosis factor inhibitors on the prevalence and incidence of new cases of CHF in RA patients, and an improvement in the structure and function of the heart during therapy has been shown. Inhibitors of interleukin (IL) -1, inhibitors of IL-6, inhibitors of T-cell co-stimulation, anti-B-cell therapy, targeted csDMARDs do not increase the risk of CHF and may have cardioprotective effects, including slowing the progression of left ventricle myocardial dysfunction. Due to the high risk of CHF and CHF-associated mortality in RA patients, early diagnosis of cardiac dysfunction, development of a prevention and treatment strategies are needed, including high-quality prospective studies to assess the effect of anti-rheumatic therapy on myocardial function, risk of developing and decompensation of CHF in RA patients. It is possible that some drugs may possess protective effects on cardiomyocytes so they could become the first-line drugs in patients with CHF or the risk of its development.
Collapse
|
10
|
Panafidina T, Popkova TV, Novikova DS. P4450Atherosclerosis in women with systemic lupus erythematosus with and without nephritis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Nephritis in systemic lupus erythematosus (SLE) is a factor contributing to early development of atherosclerosis (AS).
Objectives
The aim of the study is to determine differences in cardiovascular risk factors and AS in SLE pts with and without lupus nephritis (LN).
Methods
The study included 162 females, age 35 [26–43] years (median [interquartile range 25–75%])) with SLE (ACR,1997). We divided SLE pts on two groups, comparable in age: the 1st group is the pts with LN (n=84, 52%), the 2nd - without LN (n=78, 48%). We considered traditional factors of cardiovascular disease (CVD): (smoking, family history of CVD, blood pressure, cholesterol (total, HDL, LDL) and triglyceride (TG) levels, body mass index, diabetes mellitus) and SLE-related factors (age at onset, duration, clinical features, SLE Disease Activity Index (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics damage index (SLICC/DI), treatment with steroids); intima-media thickness (IMT) and the 10-year risk for coronary events. Carotid intima-media wall thickness of common carotid arteries was measured by high resolution B-mode ultrasound. The 10-year risk for coronary events was estimated by the Framingham risk equation.
Results
Median SLE duration was 8,0 [2,3–17,0] years, SLEDAI 2K – 8 [3–16], SLICC/DI score – 2 [0–3], duration of prednisone treatment – 72 [26–141] months. SLE pts from the 1st group had higher prevalence of hypertension (61% vs 36%, p<0,01), systolic blood pressure (130 [110–150] vs 120 [110–130]mm Hg, p<0,01), diastolic blood pressure (80 [70–95] vs 70 [70–80] mm Hg, p<0,05), TG concentration (136 [98–184] vs 100 [61–162] mg/dl, p<0,01), Framingham Risk Score (5 [1–30] vs 1 [1–27]%, p<0,05), SLEDAI-2K (12 [5–19] vs 4 [2–10], p<0,ehz745.08501), SLICC/DI score (2 [0–4] vs 0 [0–2], p<0,01), prednisone therapy duration (95 [26–192] vs 44 [14–98] months, p<0,05), prednisone cumulative dose (34,4 [13,6–82,5] vs 15,7 [6,2–35,2] g, p<0,001), mean IMT (0,73 [0,65–0,83] vs 0,67 [0,61–0,75] mm, p<0,01), than the pts from the 2nd group. There is no difference in CVD frequency in these groups (17% vs 8%, p=0,084).
Conclusions
SLE patients with and without LN had no difference in frequency of clinical manifestations of AS (CVD), but had a greater value of mean IMT, Framingham Risk Score and a higher incidence of both traditional (hypertension, TG concentration) and SLE-related (disease activity, prednisone therapy) risk factors for AS.
Collapse
Affiliation(s)
- T Panafidina
- V.A.Nasonova Research Institute of Rheumatology, Systemic rheumatic disease, Moscow, Russian Federation
| | - T V Popkova
- V.A.Nasonova Research Institute of Rheumatology, Systemic rheumatic disease, Moscow, Russian Federation
| | - D S Novikova
- V.A.Nasonova Research Institute of Rheumatology, Systemic rheumatic disease, Moscow, Russian Federation
| |
Collapse
|
11
|
Aleksandrova EN, Verizhnikova ZG, Novikov AA, Panafidina TA, Popkova TV, Lukina GV. [Clinical value of multiplex immune assay of antinuclear antibodies in systemic lupus erythematosus.]. Klin Lab Diagn 2019; 63:434-438. [PMID: 30720960 DOI: 10.18821/0869-2084-2018-63-7-434-438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 04/24/2018] [Indexed: 11/17/2022]
Abstract
A promising trend in the diagnosis of systemic autoimmune diseases is the multiplex immune assay (MIA) of autoantibodies and other laboratory biomarkers using microchips. The aim of the work was to study the diagnostic and prognostic significance of MIA antinuclear antibody (ANA) profiles in systemic lupus erythematosus (SLE). 94 patients with SLE, 70 patients with other rheumatic diseases and 30 healthy donors were examined. ANA (antibodies to doublestranded - dsDNA, Sm, SS-A/Ro, SS-B/La antigens, nucleosomes, ribosomal protein P-RibP and ribonucleoprotein - RNP-70) were determined in the serum by MIA using the xMAP technology. In MIA, antibodies to dsDNA, Sm and RibP have a high diagnostic specificity (Sp) (95.0-99.0%) and a likelihood ratio of positive results (LR+) (9.67-15.0), i.e. are the most "useful" diagnostic tests, and antibodies to RNP-70, SS-A/Ro and nucleosomes are classified as "useful" tests for the diagnosis of SLE (Sp: 84.0-95.0%, LR+> 2.0). Determination of profiles from 3 or more antigen-specific ANA by MIA increases the Sp method to 98.0-100%, and the LR+ - to the maximum values. Profiles from 7 subpopulations of ANA (antibodies to dsDNA, Sm, RibP, SS-A/Ro,SS-B/La, nucleosomes and RNP-70, 57.9%, 71.9%, 82.5%, 61.4 %, 84.2%, 50.9%, 84.2%) were found in the chronic variant of SLE. In the acute course of the disease, 4 subpopulations of ANA are simultaneously detected (antibodies to dsDNA, Sm, SS-A/Ro and nucleosomes, 77.3%, 45.5%, 40.9% and 72.7%); in subacute course there are 2 subpopulations of ANA (antibodies to dsDNA and nucleosomes, 53.3% and 46.7%). The activity index of SLEDAI-2K positively correlates with the concentration of antibodies to dsDNA (r = 0.55, p < 0.05), nucleosomes (r = 0.65, p < 0.05), RibP (r = 0.32; p < 0.05) and Sm (r = 0.36, p < 0.05) in the blood. There was no reliable relationship between the production of varieties of ANA and the index of organ damage. Mucocutaneous disorders, lupus-nephritis and neurolupus were most often associated with the detection of antibodies to dsDNA (53.2-64.0%), nucleosomes (55.3-66.0%), SS-A/Ro (38.0-40.4%) and Sm (27.8-36.2%). MIA of ANA profiles is an important tool for implementing a personalized approach to diagnosis, evaluation of activity, course and clinical and immunologic subtypes of SLE.
Collapse
Affiliation(s)
- E N Aleksandrova
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, 111123, Moscow, Russia
| | - Zh G Verizhnikova
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, 111123, Moscow, Russia
| | - A A Novikov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, 111123, Moscow, Russia
| | - T A Panafidina
- V.A. Nasonova Research Institute of Rheumatology, 115522, Moscow, Russia
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, 115522, Moscow, Russia
| | - G V Lukina
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, 111123, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, 115522, Moscow, Russia
| |
Collapse
|
12
|
Abstract
According to modern ideas, chronic low-grade inflammation, which development is associated with uncontrolled activation of both innate and adaptive immunity, plays a fundamental role in all stages of the atherosclerotic process. The contribution of inflammation to the development of atherosclerotic vascular lesions attracts attention to the similarity of the mechanisms of immunopathogenesis of atherosclerosis and classic inflammatory rheumatic disease - rheumatoid arthritis. In the aspect of participation in the pathogenesis of atherosclerotic vascular lesions and as a promising therapeutic "target" of particular interest is interleukin-1β (IL-1β), which plays an important role in the development of many acute and chronic immunosuppressive diseases. The mechanisms of atherosclerosis associated with IL-1β determine the ability of cholesterol crystals and other "Pro-atherogenic" factors to induce the synthesis of IL-1β by activating NLRP3 inflammasome. The mechanisms of atherosclerosis associated with IL-1β determine the ability of cholesterol crystals and other "proatherogenic" factors to induce the synthesis of IL-1β by activating NLRP3 inflammasome. Convincing evidence for the role of inflammation in development of atherosclerosis in General and good prospects of anti-inflammatory therapy in particular obtained in a randomized placebo-controlled study called CANTOS (Canakinumab Anti-inflammatory Thrombosis Otcomes Study), which studied the effectiveness of treatment with monoclonal antibodies to IL-1β canakinumab (Novartis International AG) in patients with severe atherosclerotic vascular lesions as a new approach to secondary prevention of cardiovascular complications. The results of CАNTOS research, as well as the experience gained in rheumatology in regard to cardiovascular effects of innovative anti-inflammatory drugs, have great importance for the improvement of secondary prevention of atherosclerosis-related cardiovascular complications.
Collapse
Affiliation(s)
- E L Nasonov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia.,I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
13
|
Gerasimova EV, Popkova TV, Martynova AV, Markelova EI, Novikova DS, Kirillova IG. [Level of N-terminal fragment of brain natriuretic peptide progenitor and atherosclerotic damage of brachocephalic arteries in patients with rheumatoid arthritis with inefficiency and/or injurability of basic anti - inflammatory treatment]. TERAPEVT ARKH 2019; 91:34-39. [PMID: 32598674 DOI: 10.26442/00403660.2019.05.000286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Indexed: 11/22/2022]
Abstract
The high prognostic significance of the concentration of the N-terminal - pro-B-type natriuretic peptide (NT-proBNP) in the development of cardiovascular diseases (CVD) was identified for rheumatoid arthritis (RA) and general populations. AIM to investigate the significance of NT-proBNP level in patients (pts) with RA with the ineffectiveness and/or intolerance of basic anti - inflammatory therapy; compare the level of NT-proBNP with atherosclerotic lesion of the brachiocephalic arteries (BCA), traditional risk factors and inflammatory markers. MATERIALS AND METHODS The investigation enrolled 28 pts (24women/4men) with the lack of efficacy/resistance and/or intolerance of basic anti - inflammatory drugs (DMARDs); median age was 55 [46; 61] years, median disease duration 114 [60; 168] month; DAS28 6,2 [5.1; 7.0]; SDAI 35.0[23.9; 51.0], CDAI 30.0[21.0; 42.0], serum positivity for rheumatoid factor (RF) (100%)/anti - cyclic citrullinated peptide antibodies (ACCP) (86%). The study did not include RA pts with congestive heart failure. High incidence of traditional risk factors was found in RA pts: arterial hypertension - in 75%, dyslipidemia - 61%, smoking - 17%, overweight - 61%, family history of cardiovascular diseases - 36%, hypodynamia - 68%. Coronary artery disease was diagnosed in 11% RA pts. Lack of efficacy of 3 or more DMARDs was found in 46% of pts, intolerance to previous therapy with DMARDs - in 54% pts. 47% were receiving methotrexate (20 [18; 25] mg/week), 11% - leflunomide, 7% - sulfasalazine, 46% - glucocorticoids, 75% - non - steroidal anti - inflammatory drugs. The control group consisted of 20 healthy donors, comparable to pts by age and sex. Serum levels of of NT-proBNP were measured using electrochemiluminescence method Elecsys proBNP II (Roche Diagnostics, Switzerland). The determination of the intima - media thickness (IMT) BCA were assessed from duplex scanning. Atherosclerotic lesion of BCA was assessed by the presence of atherosclerotic plaque (IMT ≥1.2 mm). RESULTS NT-proBNP concentrations in RA pts proved to be higher (78.7 [41.4; 101.3] pg/ml) than those in the control group (55.3 [36.6; 67.3] pg/ml, p100 pg/ml - 1 group (n=6) and ≤100 pg/ml - 2 group (n=22). Groups of RA pts did not differ in gender, age, activity of RA, frequency of detection of traditional risk factors. Atherosclerotic lesion of the BCA was detected in 3 (50%) pts of the 1 group and in 8 (36%) pts of the 2 group (p>0.05). In RA pts the level of NT-proBNP correlated with age (r=0.39; p.
Collapse
Affiliation(s)
- E V Gerasimova
- V.A. Nasonova Scientific and Research Institute of Rheumatology
| | - T V Popkova
- V.A. Nasonova Scientific and Research Institute of Rheumatology
| | - A V Martynova
- V.A. Nasonova Scientific and Research Institute of Rheumatology
| | - E I Markelova
- V.A. Nasonova Scientific and Research Institute of Rheumatology
| | - D S Novikova
- V.A. Nasonova Scientific and Research Institute of Rheumatology
| | - I G Kirillova
- V.A. Nasonova Scientific and Research Institute of Rheumatology
| |
Collapse
|
14
|
Abstract
Atherosclerosis is now considered as chronic inflammatory vascular disease connected to «pathological» activation of innate and adaptive immunity, characterized by lipid deposition, leukocyte infiltration and proliferation of vascular smooth muscle cells. Subclinical (low grade) inflammation plays fundamental role at all stages of atherosclerotic process progression and determines cardiovascular catastrophes development and mortality. Proinflammatory cytokines including interleukin (IL) 1, IL6, tumor necrosis factor α (TNFα), IL17, IL18, IL27, IL33, IL37 tightly interacting within cytokine network occupy an important place among numerous mediators participating in immunopathogenesis of atherosclerosis and rheumatoid arthritis. IL1β playing an important role in the development of many acute and chronic immunoinflammatory diseases attracts particular attention. IL1β significance in the development of atherosclerosis is determined by many mechanisms including procoagulant activity, enhancement of monocytes and leucocytes adhesion to vascular endothelium, vascular smooth muscle cells growth and others. Fundamental role of inflammation in the development of atherosclerosis is well proved in investigations of anti-atherosclerotic effect of canakinumab. Randomized placebo-controlled trial CANTOS (Canakinumab ANti-inflammatory Thrombosis Otcomes Study) assessing efficacy of canakinumab as new tool for secondary prophylaxis cardiovascular complications in general population of patients with severe atherosclerotic vascular damage. CANTOS results in combination with accumulated in rheumatology data on cardiovascular effects of anti-inflammatory drugs are of great importance for personification of approach to secondary prophylaxis of caused by atherosclerosis cardiovascular complications. They also contribute to the development of inflammatory theory of atherosclerosis pathogenesis in the whole.
Collapse
Affiliation(s)
- E. L. Nasonov
- V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
| | | |
Collapse
|
15
|
Novikova DS, Udachkina HV, Kirillova IG, Popkova TV. Chronic Heart Failure in Rheumatoid Arthritis Patients (Part II): Difficulties of Diagnosis. Racionalʹnaâ farmakoterapiâ v kardiologii 2019. [DOI: 10.20996/1819-6446-2018-14-6-879-886] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Rheumatoid arthritis (RA) is characterized by a twofold increase in morbidity and mortality due to chronic heart failure (CHF). At the same time, the prevalence of CHF among RA patients is significantly underestimated. The aim of the review was to analyze the results of the main studies on the features of the clinical presentation of heart failure (HF) in RA patients, the role of visualization techniques and biomarkers in the diagnosis of HF and preclinical dysfunction of the myocardium. HF in patients with RA is characterized by a predominance of HF with a preserved left ventricular ejection fraction (LVEF). The use of clinical diagnostic criteria in RA patients can lead to both over- or underdiagnosis of CHF. Systolic dysfunction estimated by LVEF is rare in RA and does not reflect the real frequency of myocardial dysfunction. Echocardiography (ECHO-CG) with tissue Doppler echocardiography (TDE) and visualization of myocardial deformation, magnetic resonance imaging (MRI) of the heart in RA patients revealed a high frequency of HF with preserved ejection fraction, left ventricular remodeling and hypertrophy, pre-clinical systolic and diastolic dysfunction. Determination of natriuretic peptides is useful for verifying the diagnosis of HF and estimating the prognosis in this cohort, despite the possible decrease in the sensitivity and specificity of these indicators in RA patients. The review discusses the advantages of MRI of the heart, including quantitative T1 and T2 regimens, in the diagnosis of myocarditis, myocardial fibrosis, and myocardial perfusion disorders in RA patients. In order to verify the diagnosis of heart failure and detect pre-clinical myocardial dysfunction in RA patients, the determination of natriuretic peptides concentration should become part of the routine examination, beginning with the debut of the disease, along with the collection of a cardiological history, physical examination, ECHO-CT with TDE, and visualization of myocardial deformation. Evaluation of the quantitative characteristics of tissue according to MRI of the heart could improve the diagnosis of myocardial damage.
Collapse
|
16
|
Novikova DS, Kirillova IG, Udachkina HV, Popkova TV. Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis. Racionalʹnaâ farmakoterapiâ v kardiologii 2018. [DOI: 10.20996/1819-6446-2018-14-5-703-710] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
17
|
Tarasova GM, Belov BS, Bukhanova DV, Cherkasova MV, Solovyev SK, Aseeva EA, Reshetnyak TM, Popkova TV. INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. rsp 2018. [DOI: 10.14412/1995-4484-2018-433-438] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Objective: to investigate the safety and immunogenicity of 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Subjects and methods. The investigation enrolled 30 patients with a reliable diagnosis of SLE; of them there were 27 women and 3 men at the age of 19 to 62 years. The disease duration ranged from 9 months to 20 years. At the time of inclusion in the investigation, the disease activity was high in 2 patients, moderate in 3, and low in 20; five patients were in remission. During a year before vaccination, pneumonia was detected in 5 (16.7%) of the 30 patients; there were a total of 18 episodes of various respiratory and ENT infections. The patients were examined at baseline and at 1, 3 and 12 months after vaccination. Standard clinical and laboratory studies and a detailed blood immunological analysis were carried out at visits. The levels of IgG antibodies to capsular polysaccharide pneumococcus were determined during each visit. Twenty-nine patients received glucocorticoids (GCs) at a dose of 5–30 mg/day; 24 – hydroxychloroquine; 14 – cytostatics (CS); 10 – biological agents (BAs) (5 – rituximab, 5 – belimumab). A single dose of 0.5 ml of PPV-23 (Pneumo 23, Aventis) was subcutaneously injected into the upper outer arm. Vaccination was done during the ongoing therapy with GC/CS and belimumab, as well as at least 1 month before the first (next) administration and/or 4.5–5 months after the last rituximab infusion. Results and discussion. 60% of patients were observed to have mild and moderate standard local vaccine reactions; 1 (3.3%) patient had a local hyperergic reaction eliminated within 7 days of the local application of antihistamines and GCs. During the follow-up, there was no SLE exacerbation significantly associated with the vaccination performed. No new autoimmune phenomena were found in any of the cases. A year after vaccination, a significant (2-fold or more) increase in anti-pneumococcal antibody levels remained in 19 (63.3%) patients (respondents); 36.7% of patients were nonrespondents. Among the patients who received a BA, the non-responders were significantly more than among those who did not take the drug (7 (70%) and 4 (20%), respectively) (p = 0.01). When treated with rituximab and belimumab, the number of non-respondents was comparable (4 and 3, respectively). The immunogenicity of PPV-23 was independent of the degree of SLE activity: the vaccine response was absent in 1 out of the 5 patients with high (n = 2) and medium (n = 3) SLE activities, as well as in 10 out of the 25 patients with low disease activity and remission. There was no development of considerable adverse reactions after vaccination in patients with high and medium SLE activity. The overall clinical efficiency of vaccination was 93.3%. Conclusion. Thus, PPV-23 shows a good tolerability and a sufficient immunogenicity in patients with SLE. There is a need for further investigations conducted in large samples of patients during long-term follow-ups in order to more fully evaluate the clinical efficacy, tolerability, and immunogenicity of PPV-23.
Collapse
|
18
|
Krougly LB, Fomicheva OA, Karpov YA, Popkova TV, Novikova DS, Nasonov EL. [Cardiovascular Complications of Rheumatoid Arthritis: Prevalence and Pathogenesis]. Kardiologiia 2018; 56:89-95. [PMID: 28290854 DOI: 10.18565/cardio.2016.6.89-95] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with high risk of cardiovascular events. Among main causes of death in RA are: myocardial infarction, cerebrovascular accident, sudden cardiac death, which are determined by the early development and rapid progression of atherosclerotic vascular lesions. According to studies high risk of cardiovascular events is not explained by only classical risk factors. It is assumed that there are additional mechanisms of development of adverse outcomes such as systemic inflammation, increased arterial stiffness, and endothelial dysfunction. In this literature review we present various risk factors of cardiovascular events in patients with RA and their relation to RA pathogenesis.
Collapse
Affiliation(s)
- L B Krougly
- Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Center, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - O A Fomicheva
- Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Center, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - Yu A Karpov
- Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Center, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - T V Popkova
- Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Center, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - D S Novikova
- Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Center, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - E L Nasonov
- Myasnikov Clinical Cardiology Institute, Russian Cardiology Research Center, Moscow, Russia.,V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
19
|
Popkova TV, Novikova DS. ACCORDING TO THE MATERIALS OF THE 2015/2016 NEW EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) GUIDELINES FOR REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY ARTHRITIS: GENERAL CHARACTERIZATION AND DISCUSSION PROBLEMS. rsp 2018. [DOI: 10.14412/1995-4484-2018-272-279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
According to the materials of the 2015/2016 new European League Against Rheumatism (EULAR) guidelines for reducing cardiovascular risk in patients with inflammatory arthritis. The authors identify three main principles of prevention of cardiovascular diseases in rheumatoid arthritis and other chronic inflammatory arthritis and provide a general characterization of the guidelines, by reviewing the discussion problems.
Collapse
|
20
|
Karateev AE, Nasonov EL, Ivashkin VT, Martynov AI, Yakhno NN, Arutyunov GP, Alekseeva LI, Abuzarova GR, Evseev MA, Kukushkin ML, Kopenkin SS, Lila AM, Lapina TL, Novikova DS, Popkova TV, Rebrov AP, Skorobogatykh KV, Chichasova NV. RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES. ACTA ACUST UNITED AC 2018. [DOI: 10.14412/1995-4484-2018-1-29] [Citation(s) in RCA: 81] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Alekberova ZS, Ovcharov PS, Lisitsyna TA, Volkov AV, Popkova TV. [Behçet's disease: Intracardiac thrombosis (a description of two cases and a review of literature)]. TERAPEVT ARKH 2017. [PMID: 28631704 DOI: 10.17116/terarkh201789579-82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Behçet's disease (BD) is systemic vasculitis of unknown etiology, which is more common in the countries located along the Great Silk Road. The disease is diagnosed if a patient has 4 key diagnostic signs: aphthous stomatitis, genital sores, and eye and skin lesions. Vascular diseases referred to as minor criteria for BD are characterized by the formation of aneurysms and thrombosis, predominantly in the venous bed. In venous disorders, a blood clot can form in any vessel, including caval, cerebral, pulmonary, and other veins. The paper describes two clinical cases of BD with intracardiac thrombosis. In one case, a 24-year-old male patient with a documented diagnosis of BD, echocardiography revealed a left ventricular spontaneous echo contrast phenomenon that disappeared due to immunosuppressive therapy. The other case was a 34-year-old female patient, in whom the diagnosis was based on the international disease criteria: aphthous stomatitis, skin lesions (pseudopustulosis, erythema nodosum), and genital sores. Computed tomographic angiography showed a 3.7×2.2-cm mass (thrombus) in the right atrium. In addition, blood clots were present in the hepatic and inferior vena cava. No abnormalities in the coagulation system were found in both cases.
Collapse
Affiliation(s)
- Z S Alekberova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - P S Ovcharov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - T A Lisitsyna
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - A V Volkov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
22
|
Verizhnikova ZG, Aleksandrova EN, Novikov AA, Panafidina TA, Seredavkina NV, Popkova TV, Aizina NL, Nasonov EL. [THE CLINICAL INFORMATIVENESS OF AUTOMATED METHODS OF SCREENING DETECTION OF ANTI-NUCLEAR ANTIBODIES USING INDIRECT REACTION OF IMMUNE FLUORESCENCE, ENZYME-LINKED IMMUNOSORBENT ASSAY AND MULTIPLEX XMAP TECHNOLOGY UNDER SYSTEMIC LUPUS ERYTHEMATOSUS]. Klin Lab Diagn 2017; 62:173-177. [PMID: 30620533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Thew antinuclear antibodies (ANA) consist heterogeneous group of auto antibodies reacting with various components of nucleus and cytoplasm. The ANA is a main serological marker of systemic lupus erythematosus (SLE). The implementation in clinical practice of new highly productive techniques of immune analysis using automated systems sets up prerequisites for standardization and amelioration of reproducibility of detection of ANA. The study was carried out to compare diagnostic significance of automated techniques of screening detection of ANA (indirect immunofluorescence test on cells HEp-2 (IIFT-HEp-2)), enzyme-linked immunosorbent assay (ELISA) and multi-complex immune analysis (MIA, using suspension technology xMAP) in serum of patients with SLE. The serums from 94 patients with SLE were analyzed. The comparison group included 70 patients with other rheumatic diseases. The control group consisted of 30 healthy donors. The screening detection of ANA using technique IIFT-HEp-2 was implemented on automated platform AKLIDES, ELISA - on automated analyzer ALEGRIA and MIA on automated analyzer BioPlex 2200. The technique IIFT-HEp-2 demonstrated the most high diagnostic sensitivity as compared with ELISA and MIA- BioPlex 2200 (96.8%; 79.8% and 82.9% correspondingly). The general diagnostic specificity of detection of ANA using technique IIFT-HEp-2 was lower than in case of ELISA and MIO-BioPlex 2200 (40%, 70% and 57% correspondingly). In the group of healthy donors the lowest diagnostic specificity was observed in ANA screening analysis using MIA-BioPlex 2200 (80%) while in case of applying IIFT-HEp-2 and ELISA indices of diagnostic specificity made up 93.3% and 96.7% correspondingly. The ANA analysis of mix of 26 nuclear antigens using ELISA technique was a reliable laboratory test for diagnostic of SLE (likelihood ratio of positive result - 2.66). By the level of likelihood ratio of negative result of the IIFT-HEp-2 technique was more informative test for exclusion of diagnosis of SLE than techniques of ELISA and MIA-BioPlex 2200 (0.08; 0.29 and 0.3 correspondingly). The detection of ANA using technique of is the most preferable primary screening test for diagnostic of SLE. The ELISA of antibodies to mix of nuclear antigens and MIA on the basis of xMAP technology are less preferable screening tests for diagnostic of SLE as compared with IIFT-HEp-2 because of false-negative results in 20% and 17% of cases correspondingly. ELISA and MIA are to applied as confirmatory screening tests permitting to detect antigen-specific ANA in patients with SLE with positive results of IIFT-HEp-2.
Collapse
|
23
|
Gerasimova EV, Popkova TV, Novikova DS. PROATHEROGENIC LIPID AND LIPOPROTEIN METABOLIC DISTURBANCES IN PATIENTS WITH RHEUMATOID ARTHRITIS. rsp 2017. [DOI: 10.14412/1995-4484-2017-311-320] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
|
25
|
Abstract
The representatives of immunoinflammatory diseases are rheumatic ones, such as primarily rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, and other systemic connective diseases, which are characterized by a high risk for untimely death. The high risk of untimely death in these diseases has been found to be associated with the severity of an immunoinflammatory process that gives rise to severe irreversible damage to vital organs and systems and with the development of a wide spectrum of comorbidities (infections, interstitial lung disease, malignant tumors, osteoporotic fractures, etc.). Among them, diseases of the cardiovascular system, which are most commonly caused by the early development and.accelerated progression of atherosclerotic coronary lesions, hold a central.position. The paper gives the data available in the recent literature on the impact.of antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on' the cardiovascular system.
Collapse
Affiliation(s)
- E L Nasonov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - D S Novikova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
26
|
Abstract
Rheumatoid arthritis (RA) is a' disease conferring high risk for cardiovascular events (CVE). Systemic inflammation underlying RA favors development of CVE. The safety of biological agents, acting on the cardiovascular system has been inadequately investigated. On the one hand, they decrease RA activity and, on the other, may increase the risk of CVE. This review analyzes' the literature data predominantly published in recent years on the effect of an IL-6 receptor inhibitor on the cardiovascular system. Tocilizumab is shown to be a promising agent to reduce cardiovascular risk the findings need to be clinically verified. Long-term prospective investigations should be conducted to determine more exactly the impact of IL-6 receptor inhibition on. the development of CVE.
Collapse
Affiliation(s)
- T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - D S Novikova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - E L Nasonov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
27
|
|
28
|
Aseeva EA, Dubikov AI, Levasheva LA, Koilubaeva GM, Dzhetybaeva MK, Eralieva VT, Karimova ER, Isaeva BG, Kalykova MB, Saparbaeva MM, Isaeva SM, Omarbekova ZI, Solovyeva ES, Reshetnyak TM, Klyukvina NG, Popkova TV, Kosheleva NM, Lisitsyna TA, Panafidina TA, Gerasimova EV, Seredavkina NV, Kondratyeva LV, Matyanova EV, Tsanyan ME, Mesnyakina AA, Letunovich MV, Lopatina NE, Nikishina NY, Fedina TP, Sazhina EG, Glukhova SI, Solovyev SK, Nasonov EL. THE REGISTRY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS, A EURASIAN COHORT (RENAISSANCE). rsp 2016. [DOI: 10.14412/1995-4484-2016-520-526] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
29
|
Kirillova IG, Novikova DS, Popkova TV, Aleksandrova EN, Novikov AA, Gorbunova YN, Markelova EI, Korsakova YO, Glukhova SI, Volkov AV, Luchikhina EL, Demidova NV, Kasumova KA, Vladimirov SA, Kanonirova MA, Lukina GL, Karateev DE, Nasonov EL. N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs. TERAPEVT ARKH 2016; 88:19-26. [DOI: 10.17116/terarkh201688519-26] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
30
|
Kirillova IG, Novikova DS, Popkova TV, Gorbunova YN, Markelova EI, Korsakova YO, Volkov AV, Alexandrova EN, Novikov AA, Fomicheva OA, Luchikhina EL, Karateev DE, Nasonov EL. [Left and right ventricular diastolic dysfunction in patients with early rheumatoid arthritis before prescribing disease-modifying antirheumatic therapy]. TERAPEVT ARKH 2015; 87:16-23. [PMID: 26155615 DOI: 10.17116/terarkh201587516-23] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
AIM To estimate the rate of diastolic dysfunction (DD) of the left and right ventricles (LV and RV) in patients with early rheumatoid arthritis (RA) before using disease-modifying antirheumatic drugs (DMARDs) therapy and to investigate its association with traditional risk factors (TRFs) for cardiovascular diseases (CVD) and inflammatory markers. SUBJECTS AND METHODS The investigation enrolled 74 patients with a valid diagnosis of RA, including 56 (74%) women (median age, 54 years; disease duration, 7 months); the patients who were seropositive for rheumatoid factor (RF) (87%) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies (100%) who had not been on DMARDs or glucocorticosteroids. TRFs for CVD and carotid artery atherosclerosis were assessed from duplex scanning data and echocardiography was performed in all the patients with early RA before starting the therapy. The ratio of the maximum blood flow velocity during early diastolic filling (E) to that during atrial systole (A) was used as a criterion for LVDD and RVDD. There were 3 types of impaired ventricular filling: 1) E/A <1; 2) E/A = 1-2; 3) E/A > 2. RESULTS LVDD and RVDD were detected in 35 (48%) and 17 (23%) patients, respectively. RVDD was recorded only in conjunction with LVDD. Among LVDD and RVDD, the former was prevalent. All the patients with early RA were divided into 3 groups: 1) patients with LVDD and RVDD; 2) those with LVDD; 3) those without ventricular DD. All the three groups were matched for the level of DAS28, anti-CCP antibodies, and RF. The incidence of arterial hypertension, dyslipidemia, and abdominal obesity was higher in the patients of Groups 1 and 2 than in those of Group 3. There was a progressive decrease in high-density lipoprotein (HDL) cholesterol concentrations and increases in triglyceride (TG) levels and atherogenic index from Group 3 to Group 1, with the concentrations of total cholesterol and low-density lipoprotein cholesterol being similar in the 3 groups. Coronary heart disease was recorded more frequently in Group 2 than in Group 3. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) proved to be also significantly higher in the patients with DD than in those without DD. Correlations were found between LV E/A and ESR, CRP, HDL cholesterol, TG, RV E/A and ESR, DAS28, TG. CONCLUSION The patients with early-stage RA were found to have high incidence rates of LVDD and RVDD, which is related to the high prevalence of CVD, the high spread of TRF for CVD, and the high activity of an inflammatory process.
Collapse
Affiliation(s)
- I G Kirillova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - D S Novikova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - T V Popkova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - Yu N Gorbunova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - E I Markelova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - Yu O Korsakova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - A V Volkov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - E N Alexandrova
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - A A Novikov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - O A Fomicheva
- Russian Cardiology Research-and-Production Complex, Ministry of Health of Russia, Moscow, Russia
| | - E L Luchikhina
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - D E Karateev
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| | - E L Nasonov
- V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
| |
Collapse
|
31
|
Cherkasova MV, Novikov AA, Alexndrova EN, Karateev DE, Popkova TV, Luchikhina EL, Avdeeva AS, Nasonov EL. [The clinical informativeness of detection of antibodies to citrullinated proteins under rheumatoid arthritis]. Klin Lab Diagn 2015; 60:46-49. [PMID: 26027260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The main diagnostic laboratory markers of rheumatoid arthritis are IgM rheumatoid factor and antibodies to citrullinated proteins. The IgM rheumatoid factor is a sensitive but insufficiently specific marker of rheumatoid arthritis. The antibodies to citrullinated proteins have a higher specificity for diagnostic of rheumatoid arthritis. The antibodies to cyclic citrullinated peptide and modified citrullinated vimentin are the main representatives of family of antibodies to citrullinated proteins applying in clinical diagnostic practice. The study was carried out to deternine the role of antibodies to citrullinated proteins and modified citrullinated vimentin in diagnostic, evaluation of activity and severity of destructive alterations under rheumatoid arthritis. The samplings of 993 patients with reliable diagnosis of rheumatoid arthritis. 179 patients with other rheumatoid diseases and 30 healthy donors were examined. The measurement of serum concentration of IgM rheumatoid factor and C-reactive protein was implemented by immune nephelometric analysis and antibodies to citrullinated proteins were analyzed by enzymoimmunoassay The erythrocyte sedimentation rate was established using the Westergreen technique. It was established that antibodies to modified citrullinated vimentin had the highest diagnostic specificity (83%), antibodies to cyclic citrullinated peptide had the highest diagnostic specificity (87%). The diagnostic specificity of joint detection of IgM rheumatoid factor, antibodies to citrullinated proteins and antibodies to modified citrullinated vimentin made up to 87%. In patients negative to rheumatoid factor the rate ofdetection of antibodies to citrullinated proteins made up to 34% and antibodies to modified citrullinated vimentin made up to 48%. The diagnostic effectiveness of detection of antibodies to citrullinitted proteins (ratio of likelihood of positive and negative results of test was correspondingly 5.5 and 0.3; area under ROC curve 0.8) and antibodies to modified citrullinated vimentin (ratio of likelihood of positive and negative results of test was correspondingly 4.4 and 0.2; area under ROC curve 0.9) surpassed the same in analysis of IgM rheumatoid factor (ratio of likelihood of positive results--3.2, ratio of likelihood of negative results--0.4, area under ROC curve--0.8). The weak positive correlation relationship was established between concentration of antibodies to cyclic citrillinatedpeptide/antibodies to modified citrullinated vimentin in blood serum and indicators of clinical laboratory activity of rheumatoid arthritis (ESR, CRP DAS 28, (r-0.2. p < 0.05). The high positive levels of antibodies to modified citrullinated vimentin associated with expressed destructive affection of joints (p < 0.02). The antibodies to cyclic citrullinated peptide are the most highly specific and clinically informative laboratory diagnostic marker of rheumatoid arthritis. The detection of antibodies to modified citrullinated vimentin is an important additional serological test to diagnose rheumatoid arthritis in IgM rheumatoid factor-negative and/or antibodies to cyclic citrullinated peptide-negative patients and to forecast severe destructive affection of joints under the given disease. The joint study of IgM rheumatoid factor, antibodies to cyclic citrullinated peptide and antibodies to modified citrullinated vimentin under rheumatoid arthritis has higher diagnostic sensitivity as compared with isolated antibodies to citrullinated proteins.
Collapse
|
32
|
Udachkina EV, Novikova DS, Popkova TV, Panasyuk EY, Avdeeva AS, Volkov AV, Kirillova IG, Markelova EI, Aleksandrova EN, Novikov AA, Nasonov EL. Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation. Racionalʹnaâ farmakoterapiâ v kardiologii 2015. [DOI: 10.20996/1819-6446-2015-11-5-510-516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
33
|
Kirillova IG, Novikova DS, Popkova TV, Gorbunova YN, Markelova EI, Korsakova YO, Fomicheva OA, Volkov AV, Luchikhina EL, Demidova NV, Kasumova KA, Vladimirov SA, Kanonirova MA, Lukina GL, Novikov AA, Aleksandrova EN, Karateev DE, Nasonov EL. EFFECT OF «TREAT-TO-TARGET» ANTIRHEUMATIC THERAPY ON DIASTOLIC DYSFUNCTION OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING 18 MONTHS OF OBSERVATION. Racionalʹnaâ farmakoterapiâ v kardiologii 2015. [DOI: 10.20996/1819-6446-2015-11-4-398-403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
34
|
Karateev DE, Luchikhina EL, Demidova NV, Gridneva GS, Kanonirova MA, Muravyev YV, Lukina GV, Olyunin YA, Kasumova KA, Aleksandrova EN, Novikov AA, Avdeeva AA, Popkova TV, Novikova DS, Smirnov AV, Volkov AV, Nasonov EL. THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS. rsp 2014. [DOI: 10.14412/1995-4484-2014-607-614] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
35
|
Panafidina TA, Kondratyeva LV, Gerasimova EV, Gorbunova YN, Popkova TV, Nasonov EL. AB0259 Characteristics and cardiovascular comorbidities in patients with rheumatoid arthritis in a local patient cohort in russia. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.2582] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
36
|
Kondrat'eva LV, Gorbunova IN, Popkova TV, Nasonov EL. [The role of adipose tissue in rheumatoid arthritis]. Klin Med (Mosk) 2014; 92:62-67. [PMID: 25799833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM To estimate the frequency of obesity in a Russian cohort of patients with early rheumatoid arthritis (RA), determine adipocytokine (adiponectin, leptin) levels and their relation to RA activity. MATERIALS AND METHODS 47 patients with early RA fulfilling ACR/EULAR(2010) criteria and using no BAID or GC. Mean age 57 [47;62] yr, duration of disease 7 [4;8] yr, median of DAS28 5.9 [5.3; 69]. Control group included 30 age-matched healthy donors. The degree of obesity was assessedfrom metabolic syndrome criteria (NCEP/ATPIII, RSSC, WHO); leptin and adiponectin were measured by ELISA, the L/A ratio was calculated. RESULTS Patients with RA had the same mean BMI but greater waist circumference (WC) and waist/hip ratio than controls (p=0.003 and p = 0.04). Obesity was diagnosed in 63.8 and 40% of the patients in these groups (p=0.04) based on NCEP/ ATPIII criteria and in 65.9 and 40% respectively by WHO criteria. The occurrence of obesity by RSSC criteria was not significantly different (p = 0.9). In patients with RA adiponectin level was higher (p=0.04) while leptin level and L/A ratio lower (p=0.02 and 0.003) than in controls. BMI correlated with ESR, CRB, DAS28, leptin and L/A (p<0.05) in both groups. ESR positively correlated with leptin level andA/L but negatively with adiponectin level (p<0.05). CONCLUSION The study showed high prevalence ofobesity in patients with early RA and its relation to inflammation. It was associated with increased serum adiponectin level, decreased leptin level and insulin resistance.
Collapse
|
37
|
Novikova DS, Popkova TV, Gerasimov AN, Volkov AV, Nasonov EL. ASSOCIATION BETWEEN HEART RATE VARIABILITY AND COMPONENTS OF THE METABOLIC SYNDROME IN WOMEN WITH RHEUMATOID ARTHRITIS. Racionalʹnaâ farmakoterapiâ v kardiologii 2014. [DOI: 10.20996/1819-6446-2014-10-1-18-24] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
38
|
Gerasimova EV, Popkova TV, Novikova DS, Nasonov EL. [Cardiovascular diseases in patients with rheumatoid arthritis during long-term methotrexate therapy]. TERAPEVT ARKH 2014; 86:26-31. [PMID: 25026799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM To compare the prevalence of risk factors, clinical and subclinical manifestations of cardiovascular diseases (CVD) and their complications in methotrexate (MT)-treated and untreated patients with rheumatoid arthritis. SUBJECTS AND METHODS The investigation enrolled 193 patients (168 women and 25 men) less than 60 years of age (mean age 49 [44; 53] years) with RA. The patients were divided into 2 groups: 1) 69 patients who received MT in a dose of 15.1 [10.2; 21] mg/week for at least 12 months (mean disease duration 25 [18; 48] months); 2) 124 patients who did not take MT. The patient groups were matched for age, gender, disease duration, RA activity, and the rate of rheumatoid factor (RF) seropositivity and extraarticular manifestations. RESULTS Dyslipidemia was significantly less frequently identified in MT-treated patients (35/69 or 51%) than in MT-untreated ones (85/124 or 69%; p = 0.01). The serum from the patients treated with MT exhibited higher high-density lipoprotein cholesterol concentrations ((1.8 [0.9; 2.0] mmol/l) than in those untreated with MT (1.2 [1.0; 1.6] mmol/l; p = 0,047). In Group 1, hypertension (49%) and diabetes mellitus (3%) were slightly rare than in Group 2 (62 and 13%, respectively; p > 0.05). Carotid atherosclerotic plaques were found in 19 and 16% and intima-media thickness (IMT) enlargement was seen in 53 and 56% of the patients in Groups 1 and 2, respectively. Silent myocardial ischemia was diagnosed in every 10 patients; heart disease (exertional angina, myocardial infarction) was in every 5 patients in both groups. Aortocoronary bypass surgery was performed in 2 (3%) patients from those who received MT and had experienced MI and in one (1.6%) patient from the MT-untreated group. CONCLUSION Long-term MT therapy was associated with the lower rate of dyslipidemia, but it failed to affect the incidence of CVD in patients with RA.
Collapse
|
39
|
Sobchenko KE, Skripnikova IA, Novikov VE, Popkova TV, Dydykina IS, Smirnov AV, Vygodin VA, Nasonov EL, Boytsov SA. ASSOCIATION BETWEEN ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY, BONE MASS, AND OSTEOPOROSIS RISK FACTORS. Cardiovasc Ther Prev 2013. [DOI: 10.15829/1728-8800-2013-5-49-55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
| | | | | | - T. V. Popkova
- V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
| | - I. S. Dydykina
- V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
| | - A. V. Smirnov
- V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
| | | | - E. L. Nasonov
- V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
| | | |
Collapse
|
40
|
Popkova TV, Olisaeva DR, Fomicheva OA, Novikova DS, Gerasimova EV, Karpov YA, Nasonov EL. SAT0091 Invasive and Noninvasive Methods for Atherosclerosis Assessment in RA. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Gorbunova YN, Popkova TV, Novikova DS, Kondratyeva LV, Novikov AA, Cherkasova MV, Alexandrova EN, Nasonov EL. SAT0041 Metabolic Syndrome in Early and Established Rheumatoid Arthritis: Role of Adipokines. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Novikova DS, Gorbunova YN, Popkova TV, Markelova EI, Karateev DE, Nasonov EL. FRI0121 Treat to target strategy in early rheumatoid arthritis: necessity of achieving tight control of disease and aggressive monitoring of cardiovascular risk. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Udachkina EV, Novikova DS, Popkova TV, Avdeeva AS, Novikov AA, Alexandrova EN, Volkov AV, Nasonov EL. AB0306 Tocilizumab therapy resulted in significantly increased heart rate variability and improved lipid profile in patients with rheumatoid arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Novikova DS, Popkova TV, Gerasimov AN, Volkov AV, Nasonov EI. COMPARISON OF HEART RATE VARIABILITY ADJUSTED FOR AGE AND HEART RATE IN WOMEN WITH RHEUMATOID ARTHRITIS AND WOMEN WITHOUT RHEUMATIC DISEASES. Racionalʹnaâ farmakoterapiâ v kardiologii 2013. [DOI: 10.20996/1819-6446-2013-9-2-127-132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
45
|
Novikov AA, Cherkasova MV, Aleksandrova EN, Popkova TV, Luchikhina EL, Rytikova NS, Nasonov EL. [The comparative evaluation of the diagnostic value of methods of detection of antibodies to citrullinized proteins under rheumatoid arthritis]. Klin Lab Diagn 2012:50-54. [PMID: 23265058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The hyper production of large specter of autoantibodies, primarily rheumatoid factors and antibodies to citrullinized proteins, is a characteristic sign of rheumatoid arthritis. The detection of these antibodies plays an important role in diagnosing the disease, especially on its early stages. The study compared the diagnostic accuracy of different methods of detection of antibodies to citrullinized proteins under rheumatoid arthritis. The examined sample included 144 patients aged 33-58 years with reliable diagnosis of rheumatoid arthritis. The patients with systemic lupus erythematous, osteoarthritis, psoriatic arthritis, OVERLAP syndrome, ankylosing spondylitis and conditionally healthy donors consisted the comparative group. To detect antibodies to citrullinized proteins the methods of enzyme immunoassay, electrochemiluminescence, immunochromatography were applied. The study demonstrated that all the methods of detection of antibodies to citrullinized proteins have adequate diagnostic value to be implemented both in a routine clinical diagnostic practice and on the stage of screening of patients.
Collapse
|
46
|
Shul'gin DN, Olisaeva DR, Fomicheva OA, Popkova TV, Sergienko VB. [Single-photon emission computed tomography in the diagnosis of myocardial perfusion abnormalities in patients with rheumatoid arthritis: preliminary data]. TERAPEVT ARKH 2012; 84:78-80. [PMID: 22994096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Increased cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA) may be attributed to the fact that a systemic inflammation existing in this disease may trigger the development of atherosclerosis. 99mTC-MIBI (4,2-methoxyisobutyl isonitrile) is a compound that permits myocardial perfusion to be visualized and has been proposed for the evaluation of the latter in patients with RA. Analysis of the results of the studies revealed transient myocardial ischemia areas in patients who did not take methotrexate while those who used it were found to have diminished perfusion areas that were, however, clinical insignificant.
Collapse
|
47
|
Novikova DS, Popkova TV, Gerasimov AN, Volkov AV, Nasonov EL. HIGH HEART RATE AS A POTENTIAL RISK FACTOR FOR DEVELOPMENT OF CARDIOVASCULAR DISEASES IN WOMEN WITH RHEUMATOID ARTHRITIS. Racionalʹnaâ farmakoterapiâ v kardiologii 2012. [DOI: 10.20996/1819-6446-2012-8-5-636-646] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
48
|
Novikova DS, Popkova TV, Gerasimov AN, Volkov AV, Nasonov EL. THE RELATIONSHIP OF CARDIOVASCULAR RISK FACTORS AND ARTERIAL WALL STIFFNESS IN WOMEN WITH A HIGH ACTIVITY OF RHEUMATOID ARTHRITIS. Racionalʹnaâ farmakoterapiâ v kardiologii 2012. [DOI: 10.20996/1819-6446-2012-8-6-756-765] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
49
|
Lisitsyn TA, Veltishchev DY, Seravina OF, Kovalevskaya OB, Zeltyn AE, Fofanova YS, Novikova DS, Popkova TV, Nasonov EL. Objective: to specify the frequency and pattern of mental disorders in patients with rheumatoid arthritis (RA) and their association with a number of demographic parameters, stressors, inflammatory activity, duration of RA and its therapy, pain, and concomitant cardiovascular diseases (CVD).Subject and methods. One hundred and sixteen patients with verified RA were examined; 86% were women with a median age of 50 years (range, 41 to 55 years) and a median RA duration of 94.5 months (range, 45 to 228 months). Disease activity was assessed using the DAS 28 scoring system; the Brief Pain Inventory (BPI) was used for pain assessment. CVD was diagnosed by a cardiologist applying echocardiography, Doppler ultrasound, and 24-hour and blood pressure monitoring. Mental disorders were identified by a psychiatrist in accordance with ICD-10, by employing a number of psychiatric and psychological scales.Results. Mental disorders were found in 86% of the patients. There was a preponderance (85%) of anxiety-depressive spectrum disorders (ADSD): depressive episode (37%), including that within recurrent depressive disorder (19%); dysthymia (23%); adjustment disorders (16%); and generalized anxiety disorder (9%). Moderate cognitive impairment was revealed in 52% of the patients with ADSD. Schizophrenia was detected in 1%; 76 % of the RA patients had sleep disorders; 63 and 52% reported a stressful event at the onset of RA or before its exacerbation, respectively. The patients with ADSD did not differ from those without ADSD in age, gender, disease duration and activity, but they had more frequently aseptic bone necroses (ABN), X-ray stage IV, Class III functional insufficiency (FI), higher severity index and HAQ index. The patients with ADSD experienced stronger pain (p < 0.05). They took glucocorticoids for a shorter time (p < 0.05). Basic anti-inflammatory drugs were taken by the patients with and without ADSD at a similar frequency, but the patients with ADSD received methotrexate less often. ADSD was more common in patients with RA and CVD (angina pectoris, atherosclerosis, acute cerebrovascular insufficiency). Conclusion. Mental disorders with a predominance of ADSD are typical of the majority of patients with RA. Stressful events often precede the onset of RA and its exacerbation. The incidence of ADSD does not depend on age, gender, and disease duration and activity, but correlates with joint destructive changes (ABN and X-ray stage IV), pain intensity, FI, severity index and HAQ, less aggressive therapy for RA, and CVD. rsp 2011. [DOI: 10.14412/1995-4484-2011-570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
50
|
Gerasimova EV, Popkova TV, Novikova DS, Aleksandrova EN, Novikov AA, Nasonov EL. [Ten-year risk of cardiovascular complications in patients with rheumatoid arthritis]. TERAPEVT ARKH 2011; 83:14-19. [PMID: 21780651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
AIM To compare 10-year risk of cardiovascular complications (CVC) assessed by Adult Treatment Panel III (ATP III) and Reynolds Risk Score (RRS); to specify contribution of C-reactive protein (CRP) to development of CVC in patients with rheumatoid arthritis (RA). MATERIAL AND METHODS The trial included 116 RA patients (100 females and 16 males) and 85 healthy subjects (63 females and 22 males) under 55 years of age free of clinical symptoms of cardiovascular diseases. RA duration and activity were the same in men and women. The patients and controls were matched by age, incidence of standard risk factors (RF). The 10-year risk of CVC development was estimated by two scales--ATP III and RRS. Total cholesterin, HDLP cholesterin were measured with standard enzyme tests, concentration of CRP was assessed by highly sensitive immune nephelometry. RESULTS The 10-year risk of CVC was higher in RA patients both by ATP III (1.8 - 1;10%) and RRS (2.6 - 2; 7)% compared to the controls (1 - 1;3)% and (1.2 - 1;4)% (p < 0.05). In male RA patients RRS is higher than in females - 7 (3.5; 12)% and 2 (1;2)%, respectively (p < 0.001). Re-calculation from the scale ATP III to RRS has changed the risk in 17 (17%) females and 7 (44%) males with RA. As a result, the number of RA patients with a low CVC risk decreased, with a moderate risk rose 2 times, with a high risk was the same. RRS dependence on the disease duration, RA activity (DAS28) was not registered. RA patients showed a positive correlation of RRS with thickness of the intima-media complex of the carotid arteries (r = 0.44; p < 0.001). CONCLUSION Introduction of a new prognostic scale RRS allows isolation of groups of patients with moderate and high CVC risk and timely medication of such patients.
Collapse
|